A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
about
The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A?Lone atrial fibrillation: where are we now?Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.Atrial fibrillation: state of the art.Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.Suitability, efficacy, and safety of vernakalant for new onset atrial fibrillation in critically ill patients.Pharmacological management of atrial fibrillation: one, none, one hundred thousand.Meta-analysis of effect of vernakalant on conversion of atrial fibrillation.The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillationMedication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention.Costs and clinical consequences of suboptimal atrial fibrillation management.Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalolSafety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trialCurrent issues in atrial fibrillation.Novel anti-arrhythmic medications in the treatment of atrial fibrillationImpact of controlling atrial fibrillation on outcomes relevant to the patient: focus on dronedaroneEffects of pharmacologic therapy on health-related quality of life in elderly patients with atrial fibrillation: a systematic review of randomized and nonrandomized trials.Atrial fibrillation in heart failure: The sword of Damocles revisited.Almanac 2011: Cardiac Arrhythmias and Pacing. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation.Conversion of Recent-Onset Atrial Fibrillation: Which Drug is the Best?Management of atrial fibrillation in critically ill patients.Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.Update on the management of atrial fibrillation: anticoagulation and medical therapy.Update on the clinical management of atrial fibrillation: guidelines and beyond.Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis.Examining the safety of amiodarone.Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.Recent clinical trials in atrial fibrillation in hypertensive patients.Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.Pharmacological conversion of recent-onset atrial fibrillation: a systematic review.Cardioversion in atrial fibrillation. Focus on recent-onset atrial fibrillation.Contemporary approach to electrical and pharmacological cardioversion of atrial fibrillation.A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.Clinical update on the management of atrial fibrillation.Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.Vernakalant hydrochloride to treat atrial fibrillation.Vernakalant for the conversion of atrial fibrillation: the new kid on the block?Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
P2860
Q27022258-3F096105-BF6A-43FE-A755-8B3ED6206D4BQ30409016-97E8F8E0-70A2-4052-9083-42F83791E2C3Q30663685-EB069F88-31CA-4F19-AA5F-ECA1D6046138Q33359459-825B38D0-0038-4F69-A46D-C1B6B27067A6Q33589789-72A2D50E-D67D-4750-81D4-C908590D3FD6Q33678288-96D5C114-AF26-4DA0-8D38-17866206D91AQ33902193-D6A2A727-0640-4B1F-B451-E377C251E473Q34623706-C3DB2DD9-D6A2-4F40-B268-AD02AA3563B1Q34772923-1EDD7203-0946-4AB4-9C6B-AE22BABAE4BAQ35209970-D2945A99-80D1-44E8-A397-A43660DB27A4Q35885128-C0B0A4DD-1434-4D8A-BB9D-45307CCBFB1EQ35897567-5FD9B974-6178-4C1C-937A-DD7367401AB7Q36032636-8449B872-28E8-4591-B540-53F104F90C5EQ36072140-FE4C666F-14AF-4D2E-A16D-F2B4D4BA1C5AQ36382379-321EEF39-D6D5-4E4E-84A9-E78D37B55499Q36569905-EDD0FDA4-72C1-41CA-AE08-22AE1C04028CQ36584622-35A967F3-ED26-4171-AA45-336A540B4743Q37043226-F294590E-8486-4AD1-9278-8B8B265B7233Q37066818-7FCC2BFF-2979-4933-95A9-0E7E2ED03EB6Q37495803-CC7C2CBF-E38A-4770-B530-E926E9A2D9FFQ37496339-A5CCF934-0585-4470-9210-891E7EA77422Q37556650-D79440C2-BBE5-4080-B7D4-CA83F3E5DE89Q37833065-1B53A909-FDAA-4F9A-B925-6B55540620DDQ37884567-53548F81-03BF-4EBD-8626-EC54A6C5821FQ37899797-BB6F3B93-D191-49E5-9BA1-0F69627B4201Q37959147-EAB7A49A-BF7A-40F9-8769-186E3BC0E8ECQ37968223-C1D743F2-E8A1-44E4-86D1-D1D538087A56Q37983124-B9F5E00C-D240-4265-B867-99699CEDFE2AQ37993754-EF9CB5B8-A27E-4E2A-9E41-A6229EBF9547Q38009238-00E3FA9A-7756-4380-A586-1C4A967E45F0Q38013221-A60B7123-BEF7-4D70-819D-7926CC27CCEBQ38052164-96225BBD-ACE3-4E61-9B94-850C4D22CACCQ38052849-B76DC15D-7D1F-40B4-90A2-554370EBE20AQ38074334-9F8EADF9-197B-4FEF-9B4F-CE4AF53203B0Q38080598-65C3FC73-BEFA-47A3-A3FB-79CA9FDD1122Q38095871-4DFCD1A5-6695-46F7-B4B0-5C3241BDB4F1Q38103541-5DD39D60-0BA5-423E-B076-F1380438DF09Q38195102-281D6175-20B6-43CE-B912-45E560BAC1D1Q38205011-C1ED7DC2-0E48-4CCB-B0B7-3CCC7A609193Q38237297-775D31EC-E6F0-4C60-9AF9-239E9B1F91D6
P2860
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A randomized active-controlled ...... ent-onset atrial fibrillation.
@en
A randomized active-controlled ...... ent-onset atrial fibrillation.
@nl
type
label
A randomized active-controlled ...... ent-onset atrial fibrillation.
@en
A randomized active-controlled ...... ent-onset atrial fibrillation.
@nl
prefLabel
A randomized active-controlled ...... ent-onset atrial fibrillation.
@en
A randomized active-controlled ...... ent-onset atrial fibrillation.
@nl
P2093
P1476
A randomized active-controlled ...... ent-onset atrial fibrillation.
@en
P2093
A John Camm
AVRO Investigators
Alessandro Capucci
Brian Mangal
Gregory Beatch
Stefan H Hohnloser
P304
P356
10.1016/J.JACC.2010.07.046
P407
P577
2011-01-01T00:00:00Z